Results 181 to 190 of about 32,925 (256)

Cognitive function in the context of pharmacogenetic CYP2D6 variability and anticholinergic burden in older adults - results from the ActiFE study. [PDF]

Eur J Clin Pharmacol
Lorenz L, Berres J, Denkinger MD, Rothenbacher D, Braig S, Dallmeier D, Just KS.   +6 more
europepmc   +1 more source

Liquid Chromatography-Tandem Mass Spectrometry Quantification of Diet-Derived CYP2D6 Biomarkers for Clinical Phenotyping in Japanese Subjects. [PDF]

Clin Transl Sci
Kumondai M, Hayashi N, Matsumoto Y, Ebata A, Sato M, Harada-Shoji N, Tada H, Miyashita M, Ishida T, Maekawa M, Tomioka Y, Mano N.   +11 more
europepmc   +1 more source

Pharmacogenomics and Opioid Efficacy in Sickle Cell Disease: Is the Field Ready for Precision Prescribing? [PDF]

J Pers Med
Jaja C, Sop DM, Campbell A, Smith WR.
europepmc   +1 more source

CYP2D6*17 Allele [PDF]

, 2020
openaire   +1 more source

Development and Evaluation of Physiologically Based Pharmacokinetic (PBPK) Models to Investigate the Effect of CYP2D6 Polymorphism on Metoclopramide Systemic Exposure. [PDF]

Pharmaceuticals (Basel)
Shahzad I, Zamir A, Rasool MF, Alali AS, Hussain I, Alqahtani F.   +5 more
europepmc   +1 more source

A Staged Translational Framework for Evaluating Oral Glutamatergic and Senescence-Modulating Strategies in Treatment-Resistant Depression. [PDF]

Drug Des Devel Ther
Cheung N.
europepmc   +1 more source

Rudolf Buchheim Award 2026: solanidine as a dietary derived CYP2D6 biomarker. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Müller JP.
europepmc   +1 more source

Population prevalence of high-risk pharmacogenetic configurations in a healthy older Australian reference cohort. [PDF]

Front Pharmacol
Hooshmand K, Hughes S, Stocker SL, Somogyi AA, Ballinger ML, Thomas DM.   +5 more
europepmc   +1 more source